


财联社1月5日电,英国药品监管机构MHRA发表声明称,正在审查诺和诺德口服司美格鲁肽25毫克剂的许可申请,预计将在年底前作出决定。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”